טיפולים גנטיים – מחזון למציאות יום-יומית

1.Rosenberg SA, et al. N Engl J Med. 1990;323:570–78.  2. Blaese RM, et al. Science. 1995;270:475–80.  3. Sibbald B. CMAJ. 2001;164:1612.  4. BioPharm International. May 1, 2004. Available at: http://www.biopharminternational.com/genesis-gendicine-story-behind-first-gene-therapy. Accessed: September 2021.  5. Ilieva K, et al. J Mark Access Health Policy. 2020;8(1):1847808.  6. Alipogene tiparvovec: EPAR – Medicine overview. Available at: https://www.ema.europa.eu/en/documents/overview/glybera-epar-summary-public_en.pdf. Accessed: September 2021  7. Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence. EU Summary of Product Characteristics.   8. U.S. FDA. News release. August 30, 2017. Available at: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm574154.htm. Accessed: September 2021.  9. Tisagenlecleucel. US Prescribing Information. Last updated: May 2017.  10. U.S. FDA. News release. December 18, 2017. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss. Accessed: September 2021.  11. U.S. FDA. News release. October 18, 2017. Available at: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm581296.htm. Accessed: September 2021  12. Axicabtagene ciloleucel. US Prescribing Information. Available at: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel. Last updated: May 2021.  13. U.S. FDA. News release. May 24, 2019. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease. Accessed: September 2021.  14. Bluebird Bio. Press release. June 3, 2019. Available at: http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-eu-conditional-marketing-authorization. Accessed: September 2021.  15. Onasemnogene abeparvovec. EU Summary of Product Characteristics. Last updated: May 2021.  16. Onasemnogene abeparvovec: EPAR – Medicine overview. Available at: https://www.ema.europa.eu/en/documents/overview/zolgensma-epar-medicine-overview_en.pdf. Accessed: September 2021.  17. Novartis. Media release. March 19, 2020. Available at: https://www.novartis.com/news/media-releases/novartis-receives-approval-from-japanese-ministry-health-labour-and-welfare-zolgensma-only-gene-therapy-patients-spinal-muscular-atrophy-sma. Accessed: October 2021  18. ANVISA. Press release. August 17, 2020. Available at: https://g1.globo.com/ciencia-e-saude/noticia/2020/08/17/medicamento-conhecido-como-mais-caro-do-mundo-recebe-registro-da-anvisa.ghtml. (In Portuguese) Accessed: September 2021.  19. First gene therapy products approved in Brazil. September 2020. Available at: https://bricsandbeyond.blog/2020/09/01/first-gene-therapy-products-approved-in-brazil/. (In English) Accessed: October 2021.  RAR-WEB-21.23 Jun-2023